Table 1.
Clinicopathological features in patients with CCC and EC associated or not with endometriosis.
| EAOC |
Non-EAOC |
||
|---|---|---|---|
| (n = 34) | (n = 94) | ||
| Clinicopathological features | N(%)/x(_±s/M | N(%)/x(_±s/M | p |
| Age | |||
| Mean ± SD | 48.65 ± 8.98 (32–63) |
54.39 ± 9.05 (31–74) |
0.002* |
| Median age of menarche | 13 | 14 | 0.001* |
| Menopausal status | 0.211 | ||
| Premenopausal | 11 (32.36%) | 42(44.68%) | |
| Postmenopausal | 23 (67.64%) | 52 (55.32%) | |
| Personal history | |||
| Infertility | 9 (26.47%) | 10 (10.64%) | 0.026* |
| Symptoms | |||
| Dysmenorrhea | 15 (44.12%) | 22 (23.40%) | 0.022* |
| Pelvic pain | 18 (52.94%) | 42 (44.68%) | 0.408 |
| Abdominal distension | 14 (41.18%) | 31 (32.40%) | 0.391 |
| Menstrual disorder | 12 (35.29%) | 17 (18.09%) | 0.040* |
| Vaginal bleeding | 6 (17.65%) | 24 (25.53%) | 0.352 |
| Tumor diameter (cm) | 12.15 | 10.00 | 0.100 |
| Histology | 0.207 | ||
| EC | 16 (47.06%) | 56(59.57%) | |
| CCC | 18 (52.94%) | 38(40.43%) | |
| FIGO stage | 0.032* | ||
| I–II | 31 (91.18%) | 69 (73.40%) | |
| III–IV | 3 (8.82%) | 25 (26.60%) | |
| EC grade | 0.228 | ||
| Low grade | 11(68.75%) | 29 (51.79%) | |
| High grade | 5(31.25%) | 27 (48.21%) | |
| Ascites | 15 (44.12%) | 60 (63.83%) | 0.046* |
| Tumor markers | |||
| CA125 | 0.105 | ||
| <35 U/mL | 11(32.35%) | 24 (25.53%) | |
| 35–600 U/mL | 18 (52.94%) | 38 (40.43%) | |
| >600 U/mL | 5(14.71%) | 32 (34.04%) | |
| CA199 (U/mL) | 131.21 | 49.86 | 0.520 |
| HE4 (pmol/L) | 152.00 | 152.00 | 0.369 |
*p < 0.05. EAOC, endometriosis-associated ovarian cancer; non-EAOC, non-endometriosis-associated ovarian cancer; M, median.